Liquid biopsy in hepatobiliary and pancreatic cancers: A paradigm shift in early detection, prognostic stratification, and perioperative monitoring

Table 2 Role of liquid biopsy in tumor profiling

No.	Title of study	Ref.	Conclusion of study
1	The growing role of precision and personalized medicine for cancer treatment	Krzyszczyk et al[51], 2018	Highlights advancements in precision medicine and its role in tailoring cancer treatments based on genetic and molecular markers
2	CTC as liquid biomarker for high HCC recurrence risk after curative liver resection	von Felden et al[52], 2017	Suggests that CTCs can serve as a prognostic biomarker for high recurrence risk in HCC patients after liver resection
3	Precision medicine of hepatobiliary and pancreatic cancers: Focusing on clinical trial outcomes	Tsumura et al[53], 2022	Reviews the role of precision medicine in hepatobiliary and pancreatic cancers, emphasizing clinical trial findings
4	Bile liquid biopsy in biliary tract cancer	Liu et al[54], 2023	Supports the use of bile liquid biopsy for diagnosing and monitoring biliary tract cancer
5	Bile cellfree DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer	Shen et al[55], 2019	Demonstrates that bile cfDNA can detect somatic mutations, aiding in the diagnosis of biliary tract cancer

CTC: Circulating Tumor Cells; HCC – Hepatocellular carcinoma; cfDNA: Cell free DNA.